EBRO 2017

NCT00004054

RTOG-9902: Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302 Primary endpoint: 5-year OS

RT 70.2 Gy(RBE)+ ADT 24 m.

Random

RT 79.2 Gy(RBE) + ADT 24 m. + paclitaxel, estramustine, and oral etoposide

No significant differences in OS, biochemical failure, local progression, distant metastases, or disease-free survival with the addition of adjuvant CT to LT AS þ RT.